Table 3. Univariate cox regression analyses about one-year cardiovascular mortality for all patients.
| Variables | Hazard ratio | 95% CI |
|---|---|---|
| Age (years) | 1.057 | 1.042–1.072 |
| Female sex (%) | 1.976 | 1.356–2.878 |
| BMI (Kg/m2) | 0.972 | 0.924–1.022 |
| Diabetes (%) | 1.799 | 1.280–2.527 |
| Hypertension (%) | 1.201 | 0.845–1.705 |
| Prior MI (%) | 1.021 | 0.536–1.946 |
| CKD stage ≧ 3 (%) | 5.287 | 3.659–7.640 |
| Advanced HF (%) | 3.061 | 2.017–4.645 |
| Anemia (%) | 3.353 | 2.376–4.731 |
| Anterior wall (%) | 1.659 | 1.160–2.371 |
| Troponin-I (ng/mL) | 1.008 | 1.004–1.012 |
| Killip III, IV (%) | 10.132 | 6.932–10.132 |
| LVEF (%) | 0.941 | 0.928–0.954 |
| Door-to-balloon time (minutes) | 1.002 | 1.001–1.003 |
| Pain-to-reperfusion time (minutes) | 1.001 | 1.000–1.001 |
| Left main disease (%) | 2.873 | 1.768–4.670 |
| MVD (%) | 2.857 | 1.837–4.445 |
| Distal embolization (%) | 2.835 | 1.488–5.402 |
| Post-PCI stenotic severity (%) | 1.022 | 1.010–1.034 |
| DESs implantation (%) | 0.402 | 0.238–0.677 |
| Post-PCI AKI (%) | 13.008 | 9.222–18.349 |
| ACEI/ARB use (%) | 0.104 | 0.074–0.148 |
| B-blocker (%) | 0.151 | 0.104–0.218 |
| Statins use (%) | 0.134 | 0.092–0.197 |
Abbreviation: CI: confidence interval; BMI: body mass index; MI: myocardial infarction; CKD: chronic kidney disease; HF: heart failure; LVEF: left ventricular ejection fraction; MVD: multiple vessel disease; DES: drug-eluting stent; AKI: acute kidney injury; ACEI: angiotensin converting enzyme inhibitor; ARB: angiotensin receptor blocker.